BRD4 and ovarian neoplasm: Ovarian tumor models exposed to combination therapies such as ponatinib (TKi) and dBET1 (BRD4 degrader) [106], or lapatnib (TKi) and AZD5153 (BETi) [10] induced more robust cell apoptosis and tumor regression than each drug alone.